Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation
Adam Bryant(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Christopher Bredeson, Isabelle Bence‐Bruckler(University of Ottawa), Harold Atkins(University of Ottawa), Jason Tay(University of Ottawa), Sheryl McDiarmid(Ottawa Hospital), Linda Hamelin(Ottawa Hospital), Mitchell Sabloff(University of Ottawa), Lothar Huebsch(University of Ottawa), Michael Hodgins(University of Ottawa), David Allan(University of Ottawa), Dawn Sheppard(University of Ottawa), C. Elizabeth Pringle(University of Ottawa), Harry S. Hopkins(Ottawa Hospital), Grizel Anstee(Ottawa Hospital)
Cited by 103
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
|New England Journal of Medicine|2018|584
A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
|Journal of Computer Assisted Tomography|1980|503
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|435